Protagonist Therapeutics (PTGX) Interest Expenses (2015 - 2025)
Protagonist Therapeutics (PTGX) posted Interest Expenses of $501.3 million for Q4 2025, up 59507.61% sequentially from $841000.0 in Q4 2024, and up 59507.61% YoY from N/an in Q4 2024.
Protagonist Therapeutics (PTGX) Interest Expenses (2015 - 2025) Analysis & Trends
Protagonist Therapeutics has reported Interest Expenses for 11 years, with the latest figure at $501.3 million in Q4 2025.
- Quarterly Interest Expenses rose 59507.61% year-over-year to $501.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $501.3 million (up 85886.28% YoY) and the FY2025 annual result came in at $501.3 million, up 227.86% from the prior year.
- Interest Expenses climbed to $501.3 million in Q4 2025 per PTGX's latest filing, from $841000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $501.3 million in Q4 2025 and troughed at -$1.6 million in Q4 2023.
- A 5-year average of $57.5 million and a median of $2.1 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2025: Interest Expenses slumped 1039.37% in 2021, then surged 59507.61% in 2025.
- Over 5 years, Interest Expenses stood at -$1.2 million in 2021, then jumped by 156.58% to $675000.0 in 2022, then plunged by 344.0% to -$1.6 million in 2023, then soared by 151.06% to $841000.0 in 2024, then soared by 59507.61% to $501.3 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $501.3 million, $841000.0, and $1.9 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 501.30 Mn |
| Dec 31, 2025 | 501.30 Mn |
| Dec 31, 2024 | 841,000.00 |
| Dec 31, 2024 | 841,000.00 |
| Sep 30, 2024 | 1.92 Mn |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 696,000.00 |
| Mar 31, 2024 | 696,000.00 |
| Dec 31, 2023 | -1.65 Mn |
| Dec 31, 2023 | -1.65 Mn |
| Sep 30, 2023 | 693,000.00 |
| Sep 30, 2023 | 693,000.00 |
| Jun 30, 2023 | 92.20 Mn |
| Jun 30, 2023 | 92.20 Mn |
| Mar 31, 2023 | 63.30 Mn |
| Mar 31, 2023 | 63.30 Mn |
| Dec 31, 2022 | 675,000.00 |
| Dec 31, 2022 | 675,000.00 |